0000899243-21-049620.txt : 20211223 0000899243-21-049620.hdr.sgml : 20211223 20211223171431 ACCESSION NUMBER: 0000899243-21-049620 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211221 FILED AS OF DATE: 20211223 DATE AS OF CHANGE: 20211223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renger John CENTRAL INDEX KEY: 0001830363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 211517934 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS, INC. STREET 2: 51 ASHTOR PLACE CITY: NEW YORK STATE: NY ZIP: 10003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-21 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830363 Renger John C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02421 0 1 0 0 Chief Scientific Officer Common Stock 2021-12-21 4 M 0 7300 3.50 A 9280 D Common Stock 2021-12-21 4 S 0 7300 32.50 D 1980 D Stock Option (Right to Buy) 3.50 2021-12-21 4 M 0 7300 0.00 D 2029-04-02 Common Stock 7300 380875 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person. Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2021-12-23